Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Free Dating
Ñompany Maksim-LLC. Ýëåêòðîïðèâîäû. Made and sell.
Popular Articles

American Psychological Association Applauds Representatives Kennedy And Ros-Lehtinen For Introducing Positive Aging Act Of 2009
The American Psychological Association applauded Reps. Patrick Kennedy (D-R.I.) and Ileana Ros-Lehtinen (R-Fla.) for introducing the Positive Aging Act of 2009, a longstanding legislative priority for APA that would improve access to quality mental health care for older adults by integrating mental health services into primary care and community settings where older adults reside and receive services.
new payday loan lenders
New Hope For Patients With Melanoma - The Most Deadly Form Of Skin Cancer And The Most Rapidly Increasing Cancer In The UK
Roche and Plexxikon announced interim results from a phase I study with PLX4032 (R7204) a new, highly selective and potentially promising oral treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). Patients treated with PLX4032 lived for a median of six months without their disease getting worse and more than half experienced significant shrinkage of their tumours; this included patients where the cancer had spread to the liver, lung and bone.1 Historically, less than 5% of metastatic melanoma patients are still alive five years after diagnosis.2
News of the day
New Detectors For Nuclear, Radiological Material In Cargo Should Not Be Acquired Until Testing Deficiencies Fixed, Cost-Benefit Analysis Completed
A thorough cost-benefit analysis that includes an assessment of meaningful alternatives is needed to reveal the potential security advantages of deploying new detector systems to screen cargo for nuclear and radiological materials at U.S. ports and border crossings. It is likely that the costs will exceed the savings gained from improved efficiency of the screening systems, says a new report from the National Research Council. There are shortcomings in the U.S. Department of Homeland Security"s testing of these new detector systems, therefore the DHS secretary cannot conclude whether they will consistently outperform the current ones. DHS should not proceed with further procurement of these new detector systems until the issues are addressed and the systems have been shown to be a favored option in the cost-benefit analysis.
Mental Health

Rexin-G Controls Tumor Growth And Improves Survival In Chemotherapy-Resistant Sarcoma And Osteosarcoma: Phase I/II And Phase II Studies, ASCO 2009

Epeius Biotechnologies announced the results of two related studies using Rexin-G, a tumor-targeted anti-cancer agent designed to seek-out and destroy metastatic cancers that have spread throughout the body. While Rexin-G is currently approved for the treatment of all solid tumors in the Republic of the Philippines, Epeius Biotech is conducting a series of advanced Phase I/II studies and a Phase II confirmatory trial in the U.S. The Phase I/II study evaluating the safety and efficacy of Rexin-G in chemotherapy-resistant metastatic bone and soft tissue sarcomas (ASCO Annual Meeting 2009, #10513) demonstrated that Rexin-G was well-tolerated with no dose-limiting toxicity. Moreover, Rexin-G exhibited dose-dependent efficacy in terms of tumor control rates, progression-free survival, and overall survival, thus validating both the efficiency of the tumor-targeting technology and the pharmacological mechanisms of action. The efficacy and safety of Rexin-G was further confirmed in a Phase II study for chemotherapy-resistant osteosarcoma. Again, in the absence of dose-limiting toxicity, Rexin-G was demonstrated to control tumor growth, prolong progression-free survival, and improve overall survival in osteosarcoma patients who have failed known therapies. It is important to note that these outstanding results, were achieved when Rexin-G was administered as monotherapy-unlike many other so-called targeted biologics where one or more toxic agents are used in combination in order to achieve even marginal results. Based on a critical analysis of its performance in the clinic, the U.S. FDA recently granted Rexin-G Orphan Drug Status for both soft tissue sarcoma and osteosarcoma. The results of these studies will be presented by Dr. Sant P. Chawla, Sarcoma Oncology Center, Santa Monica, CA, and discussed by Dr. Katherine Janeway, Dana-Farber Cancer Institute, Boston, MA on Saturday, May 30, 2009 at 5:00 p.m. EST/EDT. About Epeius Biotechnologies Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its high-performance gene delivery systems that are embodied in Rexin-G and Reximmune-C, a tumor-targeted cancer vaccine. Epeius Biotechnologies


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009